US-based medical software company EnsoData has acquired the sleep testing diagnostic technology from Resonea, to help patients reduce the cost of sleep apnea treatment.

Based in Arizona, Resonea develops medical-quality sleep health and wellness tools to advance the diagnosis and treatment of sleep disorders that are often hidden.

With the acquisition, EnsoData adds two new data channels to pre-screen patients for sleep apnea, extending the diagnostic capabilities of home sleep testing.

The two new tools, an acoustic flow channel and a microphone channel, will use an FDA-approved mobile app to record auditory data during sleep, and securely transfer it to the cloud.

They will enable a breath-by-breath acoustic analysis of respiratory flow and snoring to detect events indicative of sleep apnea or other disorders.

EnsoData intends to initially commercialise the new capabilities in the US, this year.

EnsoData CEO Justin Mortara said: “We are very excited to bring both acoustic flow and microphone data to the sleep community to expand the clinical data available for the health systems and providers utilizing PPG-based sleep testing.

“This is another step toward simplifying access to sleep care, helping to get more patients with sleep disorders diagnosed and ultimately connected with therapy.

“As a leader in healthcare AI solutions, EnsoData’s device-agnostic approach using pulse oximeters (PPG) and now smartphones supports our strategy to deploy flexible solutions that can easily scale to address the unmet clinical needs for sleep testing in the US and globally.”

According to the company, sleep apnea is an underdiagnosed condition that worsens cardiovascular and neurodegenerative diseases, along with metabolic disorders.

The early identification and treatment of sleep apnea will help reduce healthcare expenses, improve population health, and impact healthcare economics.

Currently, sleep apnea screening involves face-to-face patient-to-physician conversations and sleep health screening questionnaires, which limit the accessibility and scalability of screening.

EnsoData said that the new microphone and acoustic flow channels use the patient’s existing smartphone, without needing any proprietary medical hardware.

The two channels provide a mobile-first, data-driven approach to sleep apnea pre-screening, and allow physicians to conduct sleep studies at home, said the medical technology company.